gutflix
GI learning, personalised

Summary

NIVOLUMAB AS MONOTHERAPY IN CIRRHOTIC PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA NON RESPONDERS TO PREVIOUS SYSTEMIC THERAPY

Paolo Pochettino

UEG Week Copenhagen 2023 | Poster

Hepatobiliary

October 15, 2023

A single-centre retrospective study of 22 cirrhotic patients with advanced HCC treated with off-label nivolumab monotherapy after TKI failure or intolerance reported median overall survival of 7.8 months, with radiological or biological response at 3 months predicting longer survival.

KEY POINTS

- Median overall survival was 7.8 months (95%CI 4.7-14.2) in the overall cohort of 22 patients, with 68% surviving beyond 6 months.
- Patients achieving radiological response at 3 months had median OS of 27.7 months versus 6.4 months in those with disease progression (p=0.0003).
- Biological response (≥25% AFP decrease) at 3 months was also associated with improved survival (p=0.0001).
- Baseline factors associated with better OS included ECOG 0 performance status (p=0.031), presence of metastatic lymph nodes (p=0.040), and monolobar disease (p=0.009).
- Grade 3-4 adverse events occurred in 5 patients (pulmonary thromboembolism in 2, variceal bleeding, autoimmune colitis, and severe asthenia in 1 each).

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e89bf66c-743b-11ee-b3c3-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.